10-Q: Precipio Q3 2025: Revenue Growth Amidst Going Concern Doubts

Precipio, a cancer diagnostics company, reported significant revenue growth in Q3 2025 and the nine months ended September 30, 2025, but continues to face substantial doubt about its ability to continue as a going concern.

Summary

• Net sales for the three months ended September 30, 2025, increased by $1.5 million (30%) to $6.8 million compared to $5.2 million in the same period of 2024.
• Net sales for the nine months ended September 30, 2025, increased by $4.3 million (33%) to $17.4 million compared to $13.1 million in the same period of 2024.
• Patient diagnostic service revenue increased by 34% in Q3 2025 and 38% for the nine months, driven by a 19% and 25% increase in cases processed, respectively.
• Gross profit for the nine months ended September 30, 2025, increased by $1.9 million to $7.6 million, with gross margin improving to 44% from 38% in the prior year.
• Operating loss for the three months ended September 30, 2025, significantly improved to $(61) thousand from $(597) thousand in Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $(889) thousand, a substantial improvement from $(3.9) million in the same period of 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, was $0.3 million, compared to net cash used of $(0.1) million in the prior year.
• The company received approximately $0.8 million in Employee Retention Credit (ERC) payments and $1.3 million from the exercise of 100,000 warrants during the period.
• As of September 30, 2025, the company had an accumulated deficit of $103.3 million and working capital of $1.2 million.
• Substantial doubt remains about the company's ability to continue as a going concern for the next twelve months.

Sentiment

Score: 6

Explanation: While the company shows significant revenue growth, improved gross margins, and reduced losses, the persistent 'going concern' doubt and reliance on future financing temper the overall positive sentiment. The operational improvements are strong, but the financial stability remains a key concern.

Positives

• Net sales increased significantly by 30% for the three months and 33% for the nine months ended September 30, 2025, compared to the prior year periods.
• Strong growth in patient diagnostic service revenue, driven by a 19% increase in cases processed in Q3 2025 and 25% for the nine months.
• Improved gross profit and gross margin for the nine months ended September 30, 2025 (44% vs. 38%), indicating economies of scale.
• Substantial reduction in operating loss and net loss for both the three and nine months ended September 30, 2025.
• Positive net cash flow from operating activities for the nine months ended September 30, 2025 ($0.3 million vs. $(0.1) million used in prior year).
• Receipt of $0.8 million from Employee Retention Credit (ERC) and $1.3 million from warrant exercises provided liquidity.
• Successful resolution of a legal proceeding with a former employee.

Negatives

• Continues to have substantial doubt about its ability to continue as a going concern for the next twelve months.
• Accumulated deficit of $103.3 million as of September 30, 2025.
• Reliance on raising additional financing to meet debt obligations and liabilities.
• Outstanding warrants (31,944) may not be exercised or may be exercised in a cashless manner, limiting future capital.
• The cyberattack on Change Healthcare (CHC) in February 2024 caused billing and reimbursement delays, and incurred $0.3 million in expenses in 2024, with $0.3 million still owed to CHC as of September 30, 2025.
• Operating expenses increased by $0.2 million in Q3 2025 and $0.5 million for the nine months, partly due to increased personnel costs and non-recurring office move costs.
• Customer A accounted for 27% of net sales in Q3 2025 and 26% of accounts receivable at September 30, 2025, indicating customer concentration risk.

Risks

• The ability to continue as a going concern is dependent on achieving its business plan, generating additional revenue, and raising additional financing, which is not assured.
• There is no guarantee of future proceeds from outstanding warrants, as they may never be exercised or may be exercised in a cashless manner.
• Significant political, trade, and regulatory developments, including a U.S. federal government shutdown, geopolitical instability, and changes in tax law, could have a material adverse effect on financial condition or results of operations.
• Changes to tax laws, such as those related to the capitalization and amortization of research and development expenses under Section 174 of the Internal Revenue Code, could adversely affect cash flow and financial condition.
• The healthcare industry is subject to numerous complex laws and regulations (licensure, accreditation, government healthcare program participation, reimbursement, Medicare and Medicaid fraud and abuse), violations of which could result in significant fines, penalties, and expulsion from programs.
• The outcome of legal proceedings and claims is subject to significant uncertainty and could materially and adversely affect financial statements, prevent the offering of services/products, or otherwise adversely affect operating results.
• The company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.
• Inflationary factors, such as increases in cost of goods, labor, or other operating expenses, may adversely affect operating results if price increases or cost reductions are insufficient to offset pressures.
• Customer concentration risk exists, with Customer A accounting for 27% of net sales for the three months ended September 30, 2025, and 26% of accounts receivable as of September 30, 2025.

Future Outlook

The company is actively evaluating the likelihood and timing of additional disbursements for the remaining $0.7 million Employee Retention Credit claim. It is also currently assessing the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its business, outlook, and financial statements. There can be no assurance as to the timing, amount, or certainty of receipt of additional ERC funds, and the company will continue to assess the collectability of the remaining claim. The company's ability to continue as a going concern is dependent on achieving its business plan, including generating additional revenue, and raising additional financing, if needed, with no assurance of success.

Management Comments

• Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services.
• We believe these technologies improve diagnostic outcomes across various diseases within the hematologic field.
• This structure of utilizing our clinical lab to obtain samples and utilize the equipment and staffing to develop, test and validate our products, significantly reduces the development costs and timeline for our products. This also enables us to accelerate the time to market of new product development and launch.
• As a clinical laboratory, we are always the first user of every product we develop, which allows us to optimize important laboratory functions such as workflow, inventory management, regulatory and billing issues.
• As a vendor, this enables us to serve as a reputable user of our own products, and we believe this provides us with significant credibility with existing and prospective customers.
• Because we use our products as part of our day-to-day operations, we are able to deliver a high level of hands-on, informed support to customers, improving their experience with our products.
• Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.
• Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and no evaluation of controls and procedures can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.
• Based on the evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2025.

Industry Context

Operating in the healthcare biotechnology sector, Precipio focuses on cancer diagnostics, a field driven by the need for higher accuracy and improved laboratory workflow. The company's strategy of leveraging its CLIA-certified laboratories for both R&D and revenue generation is a common model in the diagnostic industry, allowing for reduced development costs and faster time to market. Its partnerships with major global healthcare distributors like ThermoFisher, McKesson, Medline, and Cardinal Health reflect a standard go-to-market approach for diagnostic product commercialization. The impact of the Change Healthcare cyberattack highlights the broader industry's vulnerability to IT disruptions and reliance on third-party billing services. Furthermore, recent legislative changes like the One Big Beautiful Bill Act (OBBBA) and evolving tax laws, particularly concerning R&D expenses, underscore the dynamic regulatory environment affecting businesses in the U.S. healthcare and technology sectors.

Corporate Governance

Legal Proceedings

• The company is involved in legal proceedings related to matters incidental to its business.
• The company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.
• CPA Global claims approximately $0.2 million owed for patent maintenance services since February 6, 2017; a liability of less than $0.1 million has been recorded.
• A legal proceeding brought by a former employee alleging unfair dismissal and seeking monetary damages has been resolved through a settlement agreement, which was not material to the company's financial statements.
• The healthcare industry is subject to numerous complex laws and regulations (licensure, accreditation, government healthcare program participation, reimbursement, Medicare and Medicaid fraud and abuse), violations of which could result in significant fines, penalties, and expulsion from government healthcare programs.

Related Party Transactions

• The company's Chief Executive Officer provided a personal guaranty for the $250,000 Secured Loan from Altbanq Lending LLC, which has since been repaid in full.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and uncertainty due to the going concern warning, but benefit from reduced losses and revenue growth.
• Employees are impacted by increased personnel costs and receive stock-based compensation.
• Customers benefit from improved diagnostic outcomes and workflow from the company's products and services, along with high-level support.
• Suppliers and creditors are affected by delinquent accounts payable for some vendors and the ongoing repayment of Change Healthcare funds.
• Regulatory authorities continue to review and interpret healthcare laws and regulations, impacting the company's compliance obligations.

Next Steps

• Continue efforts to generate additional revenue and achieve its business plan.
• Raise additional financing, if needed, to meet debt obligations and pay liabilities arising from normal business operations.
• Actively evaluate the likelihood and timing of additional disbursements for the remaining $0.7 million Employee Retention Credit claim.
• Make equal monthly payments of approximately $83,000 through January 2026 to settle the remaining $0.3 million balance owed to Change Healthcare.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on its business, outlook, and financial statements.
• Evaluate the impact of adopting new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05, ASU 2025-06) on its financial statements and disclosures.

Key Dates

Recommendation

While Precipio demonstrated strong revenue growth and improved operational efficiency, significantly reducing its operating and net losses, the persistent 'going concern' warning presents a substantial risk. The company's ability to meet future obligations relies on generating additional revenue and securing further financing, which is not assured. The positive operational momentum is encouraging, but the underlying financial stability issues warrant a cautious 'hold' stance until there is clearer resolution on the going concern status and a more robust capital structure. Investors should monitor progress on revenue generation and financing efforts closely.

Keywords

Cancer diagnostics, Biotechnology, SEC filing, 10-Q, Financial results, Revenue growth, Net loss, Going concern, Healthcare industry, CLIA laboratories, Diagnostic products, Warrants, Employee Retention Credit, Change Healthcare cyberattack, Operating expenses, Risk factors, Corporate governance, PRPO